IP Library Granted Patent US 8,415,315
Granted Patent B2
US 8,415,315 · App. 12/706,218 · Granted Apr 9, 2013

Methods and compositions for inhibiting the proliferation of cancer cells

Inventor: Ratna Chakrabarti (Winter Springs, FL)
Assignee: University of Central Florida Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,415,315
App. No.
12/706,218
Granted
Apr 9, 2013
Kind
B2
Abstract

A method of decreasing the expression of LIM kinase 1 in a cancer cell comprising; providing an oligonucleotide consisting of the sequence of SEQ ID NO: 1; providing a cancer cell comprising an mRNA encoding LIM kinase 1; and introducing the oligonucleotide into the cancer cell, wherein the oligonucleotide decreases the expression of LIM kinase 1 in the cancer cell. The method also provides compositions of an antisense RNA LIM kinase 1 that can be administered to an individual for the purpose of inhibiting a protein kinase pathway and which further comprises methods for treating and monitoring the proliferation and metastasis of cancer cells. A kit may be used in the detection and treatment of cancer.

Claims (7)

1. A method of treating a subject exhibiting a cancer cell metastasis comprising administering to said subject a therapeutically effective dose of a composition comprising an antisense ribonucleic acid (RNA) that targets SEQ ID NO. 1.

2. The method of claim 1 , wherein said cancer cell metastasis comprises prostate cancer cells.

3. The method of claim 1 , wherein said cancer cell metastasis comprises ovarian cancer cells.

4. The method of claim 1 , wherein said cancer cell metastasis comprises breast cancer cells.

5. The method of claim 1 , wherein said cancer cell metastasis comprises lung cancer cells.

6. The method of claim 1 , wherein said administering is transdermal, intravenous, intraperitoneal or implanted adminstration.

7. The method of claim 1 wherein said subject is experiencing a recurrence of prostate cancer, and said administering comprises reducing the proliferation of prostate cancer cells.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 20, 2023
From: UNIVERSITY OF CENTRAL FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064330/0551 →
Continuity (2)
Continuation 10840737 · May 6, 2004
Related Publication 20110251255A1 · Oct 13, 2011